Friday 6 November 2026 Export SMMT’s income statement to Excel — free account

Summit Therapeutics PLC

SMMT Healthcare Biotechnology

Summit Therapeutics PLC’s revenue for fiscal 2022 (year ended December 2022) was $705,000.00.

EPS: +63.2%
Free cash flow: −112.8%

Quarter to June 2026, against a year earlier

Insider buying

15.75 1.56 +10.99%

Follow SMMT

Alert me

Market cap: $11.3B
P/E: 0.0×
Fwd P/E: 0.0×
Dividend yield: —
F-score: 3/9
Altman Z: 0.88
Beneish M: −5.00
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Summit Therapeutics PLC (SMMT) revenue by segment, product and region

Revenue by product or service $m

Line	FY2022	FY2021	FY2020
License and Service	1 100.00%	2 100.00%	1 100.00%
Revenue	1	2	1

Revenue by segment $m

Line	FY2022
Reportable Segment	1 100.00%
Revenue	1

Operating income by segment $m, and margin

	FY2022
Reportable Segment	‡
Corporate and other	‡
Operating income	‡
	‡
	‡
	‡
	‡
	‡
	‡
	‡
	‡
	‡

Revenue by region $m

Line	FY2022	FY2021	FY2020
Latin America	1 100.00%	2 100.00%	1 100.00%
United States	—	—	0 0.00%
Revenue	1	2	1

As each company reports them in its 10-K and 10-Q filings, in US dollars. Where a later filing recast a year's segments, the year is shown as recast; a period whose breakdown does not add up to the company's revenue is left out.